At the time of writing, Abbott Laboratories [ABT] stock is trading at $124.95, up 0.33%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ABT shares have gain 0.22% over the last week, with a monthly amount drifted -6.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on October 10, 2025, when The Benchmark Company initiated its Buy rating and assigned the stock a price target of $145. Previously, Jefferies upgraded its rating to Buy on July 18, 2025, and kept the price target unchanged to $145. On June 16, 2025, Leerink Partners initiated with a Market Perform rating and assigned a price target of $143 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $130 on October 08, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $131 as its price target on September 19, 2024. Edward Jones downgraded its rating to Hold for this stock on July 30, 2024. In a note dated May 30, 2024, Goldman initiated a Buy rating and provided a target price of $121 on this stock.
For the past year, the stock price of Abbott Laboratories fluctuated between $110.86 and $141.23. Currently, Wall Street analysts expect the stock to reach $153 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $124.95 at the most recent close of the market. An investor can expect a potential return of 22.45% based on the average ABT price forecast.
Analyzing the ABT fundamentals
According to Abbott Laboratories [NYSE:ABT], the company’s sales were 43.84B for trailing twelve months, which represents an 6.90% jump. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.3 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 123.87 points at the first support level, and at 122.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 125.52, and for the 2nd resistance point, it is at 126.08.
Ratios To Look Out For
It is important to note that Abbott Laboratories [NYSE:ABT] has a current ratio of 1.70. Also, the Quick Ratio is 1.24, while the Cash Ratio stands at 0.52. Considering the valuation of this stock, the price to sales ratio is 4.96, the price to book ratio is 4.26 and price to earnings (TTM) ratio is 15.67.
Transactions by insiders
Recent insider trading involved Boudreau Philip P, EVP AND CFO, that happened on Aug 08 ’25 when 5550.0 shares were sold. Officer, Boudreau Philip P completed a deal on Aug 08 ’25 to buy 5550.0 shares. Meanwhile, Director Blount Sally E. sold 2600.0 shares on Apr 30 ’25.
